Endpoints1h ago1 min read

BridgeBio Oncology slides as it tightens the scope of its KRAS program

Sep 10, 2026read at Endpoints ↗

BridgeBio Oncology Therapeutics' share price {$BBOT} plummeted by about 24% at market close Wednesday on the back of plans that it is scaling back its pipeline to focus on developing its lead KRAS inhibitor for ...

source

Reporting by Endpoints.

read at Endpoints ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

Endpoints1h ago1 min read

save

BridgeBio Oncology slides as it tightens the scope of its KRAS program

Sep 10, 2026read at Endpoints ↗

source

Reporting by Endpoints.

read at Endpoints ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?